miRNA Biomarkers in Multiple Sclerosis

• Sponsor: University of Gaziantep (Other)
• Overall Status: Completed
• CT.gov ID: NCT04772495
• Collaborator: (none)
• Enrollment: 69
• Actual Duration (Months): 26

Study Details

Study Description

Brief Summary

Multiple Sclerosis (MS) characterized by demyelination and axonal degeneration is a chronic inflammatory disease of the central nervous system (CNS). Recent studies have shown that dysregulated miRNAs alter immune responses, so they may have roles basis on various genetic diseases such as MS and may be potential targets for biomarkers and new therapeutic approaches. In this study, we evaluated the dysregulation of miRNA expression levels at MS and MS stages. We also discussed the potential of these miRNAs to be biomarkers and/or therapeutic targets in MS.

Condition or Disease	Intervention/Treatment	Phase
Multiple Sclerosis; miRNA; Epigenetic; Biomarker	Genetic: miRNA

Study Design

• Study Type: Observational
• Actual Enrollment: 69 participants
• Observational Model: Case-Control
• Time Perspective: Prospective
• Official Title: The Potential Candidate miRNA Biomarkers in Multiple Sclerosis
• Actual Study Start Date: May 1, 2015
• Actual Primary Completion Date: May 1, 2017
• Actual Study Completion Date: Jul 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Study group with Multiple sclerosis	Genetic: miRNA; miRNA effect on Multiple sclerosis pathology
Control group not Multiple sclerosis	Genetic: miRNA; miRNA effect on Multiple sclerosis pathology

Outcome Measures

Primary Outcome Measures

1. miRNA expression [intraoperative]

   peripheral blood miRNA expressions

Eligibility Criteria

Criteria

• Ages Eligible for Study: 25 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• The age of 25 years and above

• at least one Central Nervous System (CNS) demyelination event

Exclusion Criteria:

• with genetic diseases, hypertension, head trauma, neuropsychiatric disease, diabetes mellitus, hypertension, cardiac failure, hepatic failure, renal failure, Thalassemia, Sickle cell disease, iron deficiency, and B12 deficiency

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• University of Gaziantep

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Şenay Görücü Yılmaz, Assoc. Prof., University of Gaziantep
• ClinicalTrials.gov Identifier: NCT04772495
• Other Study ID Numbers: 2015/7
• First Posted: Feb 26, 2021
• Last Update Posted: Feb 26, 2021
• Last Verified: Feb 1, 2021

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Şenay Görücü Yılmaz, Assoc. Prof., University of Gaziantep: Multiple sclerosis; miRNA biomarkers; peripheral blood molecular diagnostics
• Additional relevant MeSH terms: Multiple Sclerosis; Sclerosis

Study Results

No Results Posted as of Feb 26, 2021